These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2691943)

  • 1. [Reducing the side effects of aggressive chemotherapy (cisplatin and epirubicin) with xenogenic peptides (factor AF2) in patients with hormone refractory metastatic prostate cancer. A prospective, randomized study].
    Papadopoulos I; Wand H
    Onkologie; 1989 Jun; 12 Suppl 3():26-31. PubMed ID: 2691943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of the complementary drug Factor AF2 as a supportive agent in management of advanced urothelial carcinoma. Prospective randomized multicenter study].
    Krege S; Hinke A; Otto T; Rübben H
    Urologe A; 2002 Mar; 41(2):164-8. PubMed ID: 11993095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer.
    Huan SD; Stewart DJ; Aitken SE; Segal R; Yau JC
    Am J Clin Oncol; 1999 Oct; 22(5):471-4. PubMed ID: 10521061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
    Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
    Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
    Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
    Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E
    Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group.
    Chua DT; Sham JS; Choy D; Lorvidhaya V; Sumitsawan Y; Thongprasert S; Vootiprux V; Cheirsilpa A; Azhar T; Reksodiputro AH
    Cancer; 1998 Dec; 83(11):2270-83. PubMed ID: 9840526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
    Page JP; Levi JA; Woods RL; Tattersall MN; Fox RM; Coates AS
    Cancer Treat Rep; 1985 Jan; 69(1):105-7. PubMed ID: 3881176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of third-generation epirubicin/cisplatin/xeloda adjuvant chemotherapy in patients with radically resected gastric cancer.
    Cainap C; Nagy V; Seicean A; Gherman A; Laszlo I; Lisencu C; Nadim AH; Constantin AM; Cainap S
    J BUON; 2016; 21(2):349-59. PubMed ID: 27273944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
    Petrioli R; Fiaschi AI; Francini E; Pascucci A; Francini G
    Cancer Treat Rev; 2008 Dec; 34(8):710-8. PubMed ID: 18620815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study.
    Fountzilas G; Tolis C; Kalogera-Fountzila A; Karanikiotis C; Bai M; Misailidou D; Samantas E; Athanassiou E; Papamichael D; Tsekeris P; Catodritis N; Nicolaou A; Plataniotis G; Makatsoris T; Papakostas P; Zamboglou N; Daniilidis J
    Strahlenther Onkol; 2005 Apr; 181(4):223-30. PubMed ID: 15827691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
    Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
    Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
    Eatock MM; Anthony DA; El-Abassi M; Wilson P; Paul J; Smith M; Soukop M; Evans TR
    Br J Cancer; 2000 Jun; 82(12):1925-31. PubMed ID: 10864199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.
    Içli F; Celik I; Aykan F; Uner A; Demirkazik A; Ozet A; Ozgüroğlu M; Taş F; Akbulut H; Firat D
    Cancer; 1998 Dec; 83(12):2475-80. PubMed ID: 9874451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
    Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
    Dunst J; Haensgen G
    Strahlenther Onkol; 2001 Dec; 177(12):635-40. PubMed ID: 11789401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of primary transitional cell carcinoma of the prostate responsive to combination chemotherapy with methotrexate, epirubicin and cisplatin].
    Abe K; Ohishi Y; Onodera S; Kiyota H; Asano K
    Hinyokika Kiyo; 1998 Jun; 44(6):415-7. PubMed ID: 9719942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.
    Hu W; Fang J; Nie J; Dai L; Chen X; Zhang J; Ma X; Tian G; Han J
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1129-36. PubMed ID: 24748417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
    Jang JW; Park YM; Bae SH; Choi JY; Yoon SK; Chang UI; Nam SW; Kim BS
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):415-20. PubMed ID: 15235823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.